Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology

Ingelheim, Germany,

  • The collaboration will focus on identifying new molecules to target cancers in dogs
  • Small molecules could provide superior disease control

Boehringer Ingelheim, a global leader in animal health, and CarthroniX, a biopharmaceutical company focused on developing small molecule-based therapies for degenerative and aging-related diseases, announce that they have entered into a research collaboration to pursue small molecule therapeutics in canine oncology. 

When it comes to the treatment of cancer in dogs, veterinarians have limited therapeutic options compared to other areas. Due to this unmet medical need, Boehringer Ingelheim is committed to oncology research in animal health. Under the agreement, Boehringer Ingelheim will test a select group of small molecules provided by CarthroniX with the goal of determining their impact on canine cancers. 

“Cancer is the leading disease-related cause of death in dogs. Current therapies to treat cancer in dogs are often non-specific and sometimes have significant side effects. Therefore, we are searching for new potential therapeutic options to support veterinarians in their care of animals,” says Dr. Marlene Hauck, Head of Oncology Research at Boehringer Ingelheim Animal Health. “The impressive work of CarthroniX in developing small molecules could potentially be an effective way to treat cancer.”   

“We are thrilled to combine our unique molecules with the expertise and reach of the Animal Health division of Boehringer Ingelheim. We see the potential to define a new paradigm in treating canine cancers and thus have major impacts on animal health,” says Hassan Serhan, PhD, CEO of CarthroniX.

About CarthroniX

Carthronix, Inc. is a biopharmaceutical company developing first-in-class small molecules that are designed to control chronic inflammation and harness the regenerative power of the immune system.

Boehringer Ingelheim Animal Health

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both. 
For more information visit

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contacts


Print this Press Release


Press Release Subscription

Signup here to the Boehringer Ingelheim Newsletter to receive press-releases via email.